Cholinergic nerve terminal at neuromuscular junction

The cholinergic nerve terminal at the neuromuscular junction is the presynaptic compartment of the NMJ synapse where motor neuron action potentials trigger calcium influx, leading to fusion of synaptic vesicles containing acetylcholine (ACh) with the presynaptic membrane and exocytosis into the synaptic cleft. This process, mediated by SNARE proteins and synaptotagmin as a calcium sensor, ensures precise transmission of signals to skeletal muscle fibers, initiating depolarization via postsynaptic nicotinic ACh receptors and subsequent muscle contraction. Acetylcholinesterase in the cleft rapidly degrades ACh to terminate signaling and prevent overstimulation. Dysfunctions here, such as deficient ACh release from botulinum toxin or presynaptic defects in Lambert-Eaton myasthenic syndrome and congenital myasthenic syndromes, cause muscle weakness, fatigue, or paralysis by impairing endplate potentials. Therapeutically, drugs like botulinum toxin target this terminal for controlled muscle relaxation, but risks include systemic paralysis and respiratory compromise. Understanding this site is crucial for managing NMJ disorders, where treatments often focus on enhancing ACh availability or countering presynaptic failure.

Other names

Presynaptic nerve terminalSynaptic end bulbMotor nerve terminal

Inhibition of vesicle fusion (botulinum toxin blocks SNARE-mediated exocytosis); Calcium channel modulation (enhances ACh release in LEMS treatments)